Selective Delivery of Clindamycin Using a Combination of Bacterially Sensitive Microparticle and Separable...

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Dermatology

Background:

• Diabetic foot infection (DFI) is a common complication of diabetes mellitus.
• Current treatments with clindamycin (CLY) via oral or intravenous routes cause significant side effects.
• There is a need for improved localized drug delivery methods for DFI.

Purpose of the Study:

• To develop and characterize a novel bacteria-sensitive microparticle system (MP-CLY) for clindamycin (CLY) encapsulation.
• To formulate MP-CLY into a separable effervescent microarray patch (MP-CLY-SEMAP) for enhanced skin penetration and localized delivery.
• To evaluate the dermatokinetic profile and antibacterial efficacy of the MP-CLY-SEMAP system.

Main Methods:

• Clindamycin (CLY) was encapsulated into polycaprolactone (PCL) microparticles (MP-CLY).
• MP-CLY was incorporated into a separable effervescent microarray patch (MP-CLY-SEMAP).
• Characterization included encapsulation efficiency, in vitro release studies, mechanical properties, and ex vivo dermatokinetic testing on infected skin models.

Main Results:

• MP-CLY showed high encapsulation of CLY with no chemical structure alteration.
• In vitro release demonstrated bacteria-triggered and controlled release of CLY.
• MP-CLY-SEMAP exhibited optimal mechanical properties and efficient skin penetration, leading to a 99.99% reduction in bacterial viability ex vivo.

Conclusions:

• The MP-CLY-SEMAP system represents a proof-of-concept for improved localized delivery of CLY for DFI.
• This novel delivery system enhances the dermatokinetic profile of CLY.
• Further in vivo studies in animal models are warranted to validate the efficacy and safety of MP-CLY-SEMAP.